SCHEMBL10176274

SCHEMBL10176274

Cc1csc2c(-c3ccc(C(C)(C)C)cc3)ncnc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.49
▸ MAPK1 P28482 3/20 0.49
▸ NPC1 O15118 2/20 0.40
▸ PKM P14618 1/20 0.40
▸ TNKS O95271 1/20 0.40
▸ PARP1 P09874 1/20 0.40
▸ TNKS2 Q9H2K2 1/20 0.40
▸ KIF11 P52732 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ MAPT P10636 3/20 0.36
▸ PDPK1 O15530 1/20 0.36
▸ TRPV1 Q8NER1 1/20 0.34
▸ DGAT1 O75907 1/20 0.34
▸ KIT P10721 2/20 0.33
▸ PDGFRB P09619 1/20 0.33
▸ FLT3 P36888 1/20 0.33
▸ BTK Q06187 1/20 0.33
▸ MAP3K19 Q56UN5 1/20 0.33
▸ LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24796196 0.75 NPC1 (0.48) ALDH1A1MAPK1NPC1PKMKDM4E
SCHEMBL12125904 0.73 NPC1 (0.47) ALDH1A1MAPK1NPC1PKMTNKS
SCHEMBL15125358 0.72 KDM4E (0.41) ALDH1A1TNKSPARP1TNKS2KIF11
SCHEMBL15214854 0.71 KIT (0.36) ALDH1A1MAPK1NPC1KDM4EMAPT
SCHEMBL18098806 0.69 NPC1 (0.50) ALDH1A1MAPK1NPC1PKMKDM4E
SCHEMBL25619018 0.67 TNKS (0.39) ALDH1A1TNKSTNKS2KDM4EKMT2A
SCHEMBL438101 0.67 MAPK1 (0.53) ALDH1A1MAPK1NPC1PKMKDM4E
SCHEMBL358216 0.65 NPC1 (0.50) ALDH1A1MAPK1NPC1PKMMAPT
SCHEMBL24473511 0.65 MAPK1 (0.51) ALDH1A1MAPK1NPC1PKMKDM4E
SCHEMBL1868539 0.65 NPC1 (0.50) ALDH1A1MAPK1NPC1PKMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067928-B2 Compounds and methods of use ABBVIE INC. (US) 2015-06-30 — — US disclosed
US-8518970-B2 Compounds and methods of use ABBVIE INC. (US) 2013-08-27 — — US disclosed
US-8232273-B2 Heterocyclic compounds and methods of use GENENTECH, INC. (US) 2012-07-31 — — US disclosed
US-20120184541-A1 COMPOUNDS AND METHODS OF USE ABBVIE INC. 2012-07-19 — — US disclosed
US-8114893-B2 Compounds and methods of use GENENTECH, INC. (US) 2012-02-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184541-A1 COMPOUNDS AND METHODS OF USE BCL2A1, BCL2, BAX ALDH1A1 3814/4885MAPK1 3552/4885NPC1 3311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback